인체용 황산 콜리스틴 시장 : 시장 예측(2026-2032년)

The Colistin Sulfate for Humans Market is projected to grow by USD 1,602.94 million at a CAGR of 7.12% by 2032.

Human colistin sulfate is a polymyxin antibiotic used in limited circumstances against serious infections caused by multidrug-resistant Gram-negative bacteria. Its clinical role is constrained by nephrotoxicity, neurotoxicity, dosing complexity, and the availability of safer or more targeted alternatives. Stewardship, microbiological confirmation, and specialist oversight therefore shape appropriate use.

Stewardship and Resistance Are Reshaping Clinical Use

The landscape is shifting from broad empirical reliance toward carefully justified, susceptibility-guided treatment. Hospitals are strengthening antimicrobial stewardship, infection prevention, diagnostic testing, renal-dose adjustment, and therapeutic monitoring. The emergence of mobile colistin-resistance mechanisms has further increased the importance of surveillance, agricultural controls, and coordinated public-health responses across human, animal, and environmental settings.

Artificial Intelligence Supports Safer, Evidence-Based Decisions

Artificial intelligence can contribute to colistin stewardship by accelerating resistance-pattern analysis, identifying patients at elevated toxicity risk, supporting laboratory interpretation, and improving infection-control surveillance. Its value depends on representative data, transparent validation, clinician review, and alignment with local treatment guidelines. AI should support-not replace-microbiological judgment, pharmacological expertise, and patient-specific decision-making.

Regional Insights Across Six Healthcare Environments

North America emphasizes stewardship, regulatory oversight, advanced diagnostics, and monitoring of resistant pathogens. Europe combines coordinated resistance surveillance with restrictive use policies and cross-border public-health collaboration. Asia-Pacific faces substantial resistant-infection burdens alongside varied access to diagnostics and specialist care. Latin America continues to strengthen laboratory capacity, procurement practices, and infection prevention. The Middle East is expanding tertiary-care capabilities while managing cross-border transmission risks. Africa's priorities include reliable medicine access, laboratory strengthening, surveillance, and infection-control infrastructure.

Group Insights: Multilateral Priorities and Health-System Coordination

ASEAN cooperation is particularly relevant to cross-border surveillance, laboratory networking, and harmonized stewardship. BRICS members reflect diverse burdens, health-system capacities, and resistance-control priorities, making data sharing and resilient supply systems important. The European Union supports coordinated surveillance and prudent antimicrobial policies. G7 members generally emphasize innovation, preparedness, and stewardship. GCC countries are focused on tertiary-care capacity, diagnostic quality, and regional coordination. NATO members also have interests in antimicrobial preparedness, continuity of care, and operational medicine.

Country Insights: Different Needs Within a Shared Resistance Challenge

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States generally have established stewardship and surveillance frameworks, with attention directed toward rare, severe, resistant infections and toxicity mitigation. Brazil, China, India, Mexico, and Russia are addressing heterogeneous access to diagnostics, prescribing practices, surveillance coverage, and infection-control capacity. Across all listed countries, appropriate use depends on local susceptibility data, national guidance, medicine-quality assurance, and specialist oversight.

Actions for Leaders: Protect Efficacy While Improving Patient Safety

Industry and health-system leaders should prioritize rapid susceptibility testing, standardized dosing and renal-monitoring protocols, clinical education, and transparent adverse-event reporting. They should coordinate human, veterinary, and environmental resistance surveillance; invest in infection prevention; maintain quality-assured supply channels; and evaluate new diagnostics and alternatives using clinically meaningful evidence. Governance should include audit-and-feedback systems, clear restrictions for exceptional use, and measurable stewardship outcomes.

Research Methodology: Evidence-Based Interpretation of a Specialized Therapy

This executive summary applies a qualitative synthesis framework focused on established clinical, microbiological, pharmacological, regulatory, and public-health evidence concerning human colistin sulfate. It interprets the required regional, group, and country geographies through differences in resistance surveillance, stewardship maturity, diagnostic access, infection-control capacity, and healthcare infrastructure. No market estimates, market shares, forecasts, or company-specific claims are used.

Conclusion: Colistin Sulfate Requires Precision, Oversight, and Coordination

Human colistin sulfate remains an important reserve option when severe multidrug-resistant Gram-negative infections leave few effective treatments. Its responsible role depends on precise diagnosis, susceptibility-guided prescribing, toxicity prevention, and robust resistance surveillance. Coordinated action across clinicians, laboratories, regulators, health systems, and public-health authorities is essential to preserve usefulness while protecting patients and limiting further resistance.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Colistin Sulfate for Humans Market, by Route Of Administration

• 7.1. Introduction
• 7.2. Intravenous
• 7.3. Oral

8. Colistin Sulfate for Humans Market, by Indication

• 8.1. Introduction
• 8.2. Complicated Urinary Tract Infections
• 8.3. Hospital Acquired Pneumonia
• 8.4. Skin And Soft Tissue Infections

9. Colistin Sulfate for Humans Market, by Formulation

• 9.1. Introduction
• 9.2. Powder For Injection
• 9.3. Solution

10. Colistin Sulfate for Humans Market, by Strength

• 10.1. Introduction
• 10.2. 150000 Iu/Ml
• 10.3. 250000 Iu/Ml

11. Colistin Sulfate for Humans Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Care Centers
• 11.3. Clinics
• 11.4. Hospitals

12. Colistin Sulfate for Humans Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Hospital Pharmacies
• 12.3. Online Pharmacies
• 12.4. Retail Pharmacies
  • 12.4.1. Chain Pharmacies
  • 12.4.2. Independent Pharmacies

13. Colistin Sulfate for Humans Market, by Region

• 13.1. Introduction
• 13.2. Asia-Pacific
• 13.3. North America
• 13.4. Latin America
• 13.5. Europe
• 13.6. Middle East
• 13.7. Africa

14. Colistin Sulfate for Humans Market, by Group

• 14.1. Introduction
• 14.2. ASEAN
• 14.3. GCC
• 14.4. European Union
• 14.5. BRICS
• 14.6. G7
• 14.7. NATO

15. Colistin Sulfate for Humans Market, by Country

• 15.1. Introduction
• 15.2. United States
• 15.3. Canada
• 15.4. Mexico
• 15.5. Brazil
• 15.6. United Kingdom
• 15.7. Germany
• 15.8. France
• 15.9. Russia
• 15.10. Italy
• 15.11. Spain
• 15.12. China
• 15.13. India
• 15.14. Japan
• 15.15. Australia
• 15.16. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. Market Concentration Analysis, 2025
  • 16.2.1. Concentration Ratio (CR)
  • 16.2.2. Herfindahl Hirschman Index (HHI)
• 16.3. Recent Developments & Impact Analysis, 2025
• 16.4. Product Portfolio Analysis, 2025
• 16.5. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Aurobindo Pharma Ltd.
• 17.2. Cipla Ltd.
• 17.3. Dr. Reddy's Laboratories Ltd.
• 17.4. Fengchen Group
• 17.5. Fresenius Kabi AG
• 17.6. Fujian Lifecome Biochemistry Co., Ltd.
• 17.7. Hikma Pharmaceuticals PLC
• 17.8. JSN Chemicals
• 17.9. Livzon Pharmaceutical Group Inc.
• 17.10. Lupin Ltd.
• 17.11. Mallinckrodt Pharmaceuticals
• 17.12. Mylan N.V.
• 17.13. Sandoz International GmbH
• 17.14. Shandong Lukang Pharmaceutical Co., Ltd.
• 17.15. Shengxue Dacheng Pharmaceutical
• 17.16. SNA Health Care
• 17.17. Taj Pharmaceuticals Ltd.
• 17.18. Teva Pharmaceutical Industries Ltd.
• 17.19. Xellia Pharmaceuticals ApS
• 17.20. Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.

18. Key Experts